AstraZeneca's inhaler for lung disease shows improved function in late stage trial

(Reuters) - AstraZeneca said its inhaler for chronic obstructive pulmonary disease (COPD) showed improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.